SCHEMBL70253

SCHEMBL70253

NC(=S)c1cccc(Cl)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.63
CTSL P07711 3/20 0.54
KDM4E B2RXH2 1/20 0.52
HTT P42858 1/20 0.52
GRIN2B Q13224 2/20 0.50
ALDH1A1 P00352 2/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PKM P14618 1/20 0.46
CTSB P07858 1/20 0.45
HTR3E A5X5Y0 1/20 0.45
SLC22A2 O15244 1/20 0.45
SLC22A1 O15245 1/20 0.45
SLC22A3 O75751 1/20 0.45
HTR3B O95264 1/20 0.45
PLAU P00749 1/20 0.45
HTR3A P46098 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15805914 0.83 ASH1L (0.47)
SCHEMBL8718296 0.79 PARP1 (0.54) PARP1CTSLKDM4EHTTGRIN2B
SCHEMBL9275420 0.79 PARP1 (0.54) PARP1CTSLKDM4EALDH1A1PKM
SCHEMBL11121567 0.78 PARP1 (0.53) PARP1CTSLKDM4EHTTGRIN2B
SCHEMBL11121569 0.78 PARP1 (0.53) PARP1CTSLKDM4EHTTGRIN2B
SCHEMBL2202463 0.77 PARP1 (0.63) PARP1KDM4EHTTGRIN2BPKM
SCHEMBL283924 0.77 PARP1 (1.00) PARP1KDM4EHTTGRIN2BMAPT
SCHEMBL11557655 0.77 PARP1 (1.00) PARP1KDM4EHTTGRIN2BMAPT
SCHEMBL13221047 0.77 CTSL (0.54) PARP1CTSLKDM4EHTTALDH1A1
SCHEMBL14740718 0.77 IDO1 (0.53) PARP1CTSLKDM4EHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114990587-B Electrochemical synthesis method of thiazole compound 华南理工大学 2023-05-23 CN claimed
CN-114990587-A Electrochemical synthesis method of thiazole compound 华南理工大学 2022-09-02 CN claimed
US-20250282785-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2025-09-11 US disclosed
EP-4522608-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN Pharmaceutica NV (BE) 2025-03-19 EP disclosed
CN-119546602-A Pyrrolidone derivatives as inhibitors of nfkb-induced kinase 詹森药业有限公司 2025-02-28 CN disclosed
CN-117384204-B Enol silicon ether compound, preparation method and application thereof 康龙化成手性医药技术(宁波)有限公司 2024-08-23 CN disclosed
CN-117384204-A Enol silicon ether compound, preparation method and application thereof 康龙化成手性医药技术(宁波)有限公司 2024-01-12 CN disclosed
CN-117362316-A Synthesis method of tetrahydropyrrolothiazole compound 康龙化成手性医药技术(宁波)有限公司 2024-01-09 CN disclosed
WO-2023217906-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2023-11-16 WO disclosed
EP-3555198-B1 CURABLE POLYMER LATEX COMPOSITIONS FOR THE MANUFACTURE OF RUBBER ARTICLES SYNTHOMER SDN BHD (MY) 2023-09-20 EP disclosed
CN-114990587-B Electrochemical synthesis method of thiazole compound 华南理工大学 2023-05-23 CN disclosed
EP-1119557-A1 INDENO-, NAPHTO- AND BENZOCYCLOHEPTA DIHYDROTHIAZOLE DERIVATIVES, THE PRODUCTION THEREOF AND THEIR USE AS ANORECTIC MEDICAMENTS Aventis Pharma Deutschland GmbH (DE) 2001-08-01 EP disclosed
US-6191289-B1 REACTING A 4-OXO-4H-BENZOPYRAN GROUP SUBSTITUTED WITH AMIDE OR A PHENYL GROUP IN ITS 2 POSITION IS REACTED WITH ANHYDROUS HYDRAZINE OR SALT IN PRESENCE OF CATALYST FOLLOWED BY REACTING WITH NITROUS ACID OR SALT TO FORM TETRAZOLE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-02-20 US disclosed
US-6090833-A EATING DISORDERS; ANTIDIABETIC AGENT AVENTIS PHARMA DEUTSCHAND GMBH (DE) 2000-07-18 US disclosed
WO-2000018749-A1 INDENO-, NAPHTO- AND BENZOCYCLOHEPTA DIHYDROTHIAZOLE DERIVATIVES, THE PRODUCTION THEREOF AND THEIR USE AS ANORECTIC MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-04-06 WO disclosed
US-5874593-A SULFUR CONTAINING AMIDE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1999-02-23 US disclosed
US-5614520-A 2-arylthiazole derivatives and pharmaceutical composition thereof TEIJIN LIMITED (JP) 1997-03-25 US disclosed
EP-0513379-B1 2-ARYLTHIAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME TEIJIN LTD (JP) 1996-09-11 EP disclosed
EP-0711762-A1 PROCESS FOR PRODUCING TETRAZOLE COMPOUND AND INTERMEDIATE THEREFOR SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1996-05-15 EP disclosed
EP-0513379-A1 2-ARYLTHIAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME TEIJIN LIMITED (JP) 1992-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282785-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE NFKBIA, IKBKG, IKBKB PARP1 699/4885CTSL 3669/4885KDM4E 1355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.